Human TGF-β Antibody - Fresolimumab Biosimilar

Human IgG4 (S228P) - CAS #948564-73-6

ABOUT

Anti-human TGF-β1, β2, β3- Fresolimumab biosimilar - CAS #948564-73-6

Anti-hTGF-β-hIgG4 (S228P) is a biosimilar antibody of Fresolimumab, a human transforming growth factor beta (TGF-β) antibody that blocks all mammalian active subtypes of TGF-β: TGF-β1, TGF-β2, and TGF-β3. This monoclonal antibody (mAb) is under investigation for the treatment of pulmonary fibrosis and various cancer types (non-small cell lung cancer).

More details More details

Anti-hTGF-β-hIgG4 (S228P) comprises the variable region of Fresolimumab and the human IgG4 (S228P) constant region of Fresolimumab for low/no effector functions.

This antibody can be used together with HEK-Blue™ TGF-β cells for screening and neutralization assays to block TGF-β signaling induced by recombinant human TGF-β (see figure).

 

Key features

  • Each lot is functionally tested and validated.
  • The complete sequence of the antibody construct has been verified.
  • The absence of endotoxins is determined by the EndotoxDetect™ assay.

 

All products are for research use only, and not for human or veterinary use.

Binding of Anti-TGF-β Fresolimumab
Binding of Anti-TGF-β Fresolimumab

SPECIFICATIONS

Specifications

Target

TGF-β1, hTGF-β2, hTGF-β3

Target species

Human

Species
Human
Isotype
hIgG4 (S228P)
kappa
Recommended isotype control
Human IgG4 (S228P) Isotype Control Antibody
Clone
Fresolimumab
CAS number
948564-73-6
Synonyms
GC1008
Molecular weight
144.4 kDa
Tag
Tag-free
Source
CHO cells
Production details
Animal-free
Purification
Protein A
Formulation buffer

Sodium phosphate buffer with glycine, saccharose, and stabilizing agents

Preservative
Azide-free
Purity
≥ 95 %
Appearance (form)
Lyophilized
Reconstitution buffer
Sterile water (not provided)
Endotoxin

Negative (tested using EndotoxDetect™ assay)

Tested applications

Neutralization assay, ELISA

Quality control

Each lot is functionally tested and validated.

CONTENTS

Contents

  • Product: 
    Anti-hTGF-β-hIgG4 (S228P)
  • Cat code: 
    htgfb-mab14
  • Quantity: 
    100 µg

Shipping & Storage

  • Shipping method:  Room temperature

    • Storage:

    • -20 °C
    Stability: -20°C for up to 1 year

    Caution:

    • Avoid repeated freeze-thaw cycles

Details

Fresolimumab background

Fresolimumab is a fully human IgG4 (S228P) monoclonal antibody (mAb) designed to target the transforming growth factor beta (TGF-β) [1]. As a pan-specific mAb, it binds and neutralizes all three active mammalian isoforms of TGF-β: TGF-β1, TGF-β2, and TGF-β3 [1].

TGF-β is a multifunctional cytokine that regulates critical cellular processes such as proliferation, apoptosis, differentiation, and migration [2,3]. Dysregulated TGF-β signaling is implicated in several fibrotic diseases (e.g., idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD)) and plays a role in cancer development and progression [1].

Fresolimumab (GC-1008) has been shown to inhibit the pathological effects of excessive TGF-β activity and was developed as a potential treatment for IPF, melanoma, renal cell carcinoma, and focal segmental glomerulosclerosis [1]. Currently, it remains under clinical investigation for its potential efficacy in osteogenesis imperfecta and non-small cell lung cancer (NSCLC) [4].

 

References:

1. Grütter C, et al., 2008. A cytokine-neutralizing antibody as a structural mimetic of 2 receptor interactions. Proc Natl Acad Sci U S A. 105(51):20251-6.
2. Travis MA. & Sheppard D., 2014. TGF-β activation and function in immunity. Annu Rev Immunol. 32:51-82.
3. Taylor AW., 2009. Review of the activation of TGF-beta in immunity. J Leukoc Biol. 85(1):29-33.
4. https://www.pharmaceutical-technology.com/data-insights/fresolimumab-sanofi-non-small-cell-lung-cancer-likelihood-of-approval/?cf-view

You may also need

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?